Overview of Vendios

Quick Facts

Property	Description
Active ingredient	Diosmin
Form	Film-coated tablet (Oral dosage form)
Pharmacological class	Phlebotropic agent, Venotonic drug
General purpose	Supports venous circulation and capillary protection
Origin	Semisynthetic bioflavonoid derivative

Vendios is a monocomponent pharmaceutical preparation classified as a phlebotropic agent and a venotonic drug, primarily focusing on the maintenance of vascular health. This medication is taken systemically to address fundamental issues related to insufficient venous function and microcirculation. Pharmacological studies support the general effectiveness of these compounds in improving vascular tone.

Defining Vendios: Type and Pharmacological Class

Vendios is specifically categorized within the therapeutic class of phlebotropic agents and venotonic drugs, signifying its targeted action on the walls of veins and capillaries. The active substance, Diosmin, is grouped under the code C05CA, which designates Bioflavonoids used as capillary stabilizing agents. This classification indicates the drug's primary pharmacological purpose is to specifically enhance the tone and health of the venous return system, distinguishing it from general cardiac or arterial medications.

Composition, Origin, and Dosage Form

The Active Pharmaceutical Ingredient (API) in Vendios is Diosmin, a substance chemically defined as a flavonoid glycoside and a bioflavonoid. Diosmin is typically produced as a semisynthetic compound, derived from natural plant sources but chemically optimized for enhanced therapeutic consistency. Vendios is presented as an oral dosage form, specifically a film-coated tablet, which allows for systemic administration and absorption into the bloodstream for widespread effect.

Primary Action and General Therapeutic Purpose

The general therapeutic purpose of Vendios is to improve the functional health of the venous system through actions that include vascular toning and capillary protection. As a capillary stabilizing agent, the medication helps to decrease the abnormal permeability of the small blood vessels and enhance their resistance. These actions facilitate venous return and support better microcirculation, aiming to relieve the basic physiological compromise associated with poor blood flow in the veins.

What side effects are possible with Vendios?

Possible Side Effects and Safety Information

The safety profile of Vendios, as documented in official regulatory sources, defines adverse reactions primarily by their frequency and affected physiological system. The adverse effects profile is largely focused on the digestive tract and is classified using standard regulatory frequency bands.

Official Adverse Reaction Classifications

Adverse reactions documented in the Summary of Product Characteristics (SmPC) framework involve three main System-Organ Classes:

Gastrointestinal disorders
Nervous system disorders
Skin and subcutaneous tissue disorders

The most frequently reported adverse reactions are classified as Common, affecting up to 1 in 10 users, and typically involve the digestive system, such as diarrhoea, dyspepsia, nausea, and vomiting. Effects classified as Rare include headaches, dizziness, and various forms of rash or hives (urticaria).

Serious Reactions and Safety Limitations

Regulators have not classified any adverse event of this medicine as an Important Identified Risk in official Risk Management Plans. However, the potential for rare but clinically significant severe allergic reactions, such as Quincke's oedema (angioedema), is noted, though its frequency is unknown.

Safety Restrictions and Special Populations

The primary regulatory limitation is hypersensitivity (allergy) to the active substance or any excipients. Furthermore, official safety statements advise caution or avoidance in specific populations due to a lack of sufficient data:

Pediatric Use: Safety and efficacy in children and adolescents under 18 years of age have not been established.
Pregnancy and Breast-feeding: Use is generally inadvisable as a precautionary measure due to absent or limited human safety data.

Overdose and Emergency Response

Overdose and when to seek help for Vendios

Official regulatory documentation states that clinical experience with Vendios (Diosmin) overdose is limited. When documented cases of excessive intake have occurred, the presentation typically involves an exaggeration of commonly known undesirable effects.

Documented Overdose Manifestations

The officially reported clinical signs associated with taking more than the prescribed amount primarily involve the digestive system and the skin. These are documented in regulatory sources:

System	Documented Manifestations
Gastrointestinal	Diarrhoea, nausea, vomiting, abdominal pain, and dyspepsia.
Skin/CNS	Rash, pruritus (itching), dizziness, and headache.

Emergency Action and Management

The official guidance strictly mandates action when symptoms are present following over-exposure.

When to Seek Help: If an excessive amount of the medicine has been taken and the patient is experiencing adverse symptoms, immediate medical attention must be sought.
Antidote Status: There is no specific antidote documented for Diosmin overdose in the official labeling.
Required Management: The management of overdose should consist strictly of symptomatic and supportive treatment to address the manifested clinical signs.

Official labeling does not specify acute, severe systemic effects, such as cardiovascular or neurological complications, resulting from overdose. Regulatory information also contains no specific differential overdose considerations for populations such as children or the elderly.

Therapeutic Uses of Vendios

What Vendios Treats: Main Uses and Benefits

Vendios is applied across therapeutic domains where supportive symptomatic assistance is needed for conditions involving episodic or fluctuating manifestations of chronic venous issues. The medicine is considered relevant for the management of symptoms associated with chronic venous conditions.

The medication is commonly used to help manage the overall symptom burden in conditions such as Chronic Venous Insufficiency (CVI) and hemorrhoidal disease. It helps address symptom clusters that may become intense or disruptive, specifically sensations of physical discomfort, heaviness, functional strain, swelling (edema) in the legs, and acute, localized symptoms like pain and bleeding during hemorrhoidal flare-ups.

It is often used when symptoms intensify, providing support to help ease the overall symptom load and supports the patient during difficult episodes by easing distress. “It is applied in scenarios where additional management of discomfort is required, assists with maintaining functional stability.” Vendios is also relevant as adjunctive therapy for symptom stabilization associated with conditions like venous leg ulcers or in contexts involving heightened systemic burden.

Quick Fact: Focus on Symptomatic Support
Primary Focus	Symptoms of chronic venous discomfort and acute hemorrhoidal episodes
Key Symptom Types	Leg heaviness, functional pain, nocturnal cramps, edema, and acute rectal discomfort
Patient Benefit	Contributes to improved comfort during periods of heightened symptoms and provides supportive relief when symptoms interfere with routine activities

Regulatory References

Health Canada product information on Diosmin

Eligibility and Restrictions for Use

The eligibility for using Vendios (Diosmin) is strictly defined by official regulatory criteria, which establish the populations permitted to use the medicine and those for whom use is restricted or prohibited. Adults (18 years and older) are the population for whom use is generally established.

Contraindications and Restrictions

The medicine must not be used by patients with a known hypersensitivity or allergy to the active substance, Diosmin, or any of the inactive ingredients present in the tablet.

Population Group	Official Regulatory Status
Children and Adolescents (Under 18 years)	Not recommended; safety and efficacy are not established in this age group.
Pregnant Women	Avoidance is preferable due to limited or absent human data on use during pregnancy.
Lactating Women	Not recommended; the excretion of the substance into breast milk is unknown.

Condition-Specific Eligibility

While not typically listed as absolute contraindications, use in patients with severe hepatic or renal impairment may require cautionary review as drug metabolism and excretion could be altered. For acute symptomatic use, treatment is often restricted to a short-term course, and failure of symptoms to resolve requires re-evaluation.

What should I know about interactions with other medicines?

The official regulatory documents for Vendios (Diosmin) indicate a narrow profile of potential drug interactions, which is primarily defined by the absence of specific mandatory restrictions in the regulatory label.

Official Interaction Profile

Category	Regulatory Statement
Medicinal product categories	None documented as requiring mandatory restriction or warning in official regulatory product information.
Specific interacting medicines	No specific medicines are explicitly listed in regulatory interaction sections as absolutely prohibited or requiring mandatory dose modification.
Mechanistic basis of interactions	No specific pharmacokinetic or pharmacodynamic mechanisms are stated as the basis for a clinically relevant interaction in official prescribing information.
Timing-based interaction rules	No mandatory timing or separation requirements are specified for administration with food or other drugs.
Interaction-related restrictions	No formal restrictions, prohibitions, or mandatory avoidance rules are documented regarding interactions with food, alcohol, or herbal products.

Regulatory Classification Summary

Official product information consistently reports that no clinically relevant drug interactions have been observed or reported during established post-marketing surveillance. The regulatory classification confirms the product is not associated with formal prohibitions against other drug categories, and does not require administration timing rules. This regulatory finding reflects the product's known pharmacokinetic profile, which has not necessitated the issuance of specific warnings concerning enzyme-mediated or transporter-mediated interactions in official prescribing information.

Mechanism of Action

How Vendios Works: Selective Pathway Modulation

Vendios employs a highly selective mechanism that modulates the activity of immune cell trafficking into the alpha4beta7/MAdCAM-1-expressing areas of the gastrointestinal tract. The mechanism acts to reduce the concentration of these cells that mediate inflammatory signaling in the gut.

Targeted Immune Cell Traffic Control

This mechanism involves the drug acting as an antagonist to block the alpha4beta7 integrin protein found on the surface of circulating white blood cells. This molecular blockade prevents the immune cells from adhering to the gut lining’s blood vessels, which are marked by the partner molecule MAdCAM-1. The blockade inhibits the transition of immune cells from the bloodstream to the intestinal tissue, which limits their participation in the inflammatory cascade.

Physiological Consequence: Localized Inflammation Reduction

The core physiological consequence of controlling this cell traffic is a localized and sustained reduction in the number of inflammatory cells within the gut wall. This restriction of cell traffic results in a localized reduction in the levels of inflammatory mediators produced within the intestinal wall.

Dosage and Administration Information

How to Use Vendios

Vendios is a monocomponent preparation containing Diosmin and is administered exclusively via the oral route as a film-coated tablet. Proper use of the medicine requires adherence to specific dosing schedules that vary significantly depending on the therapeutic goal—either managing a chronic condition or addressing an acute episode.

Official Dosing Regimens for Adults

The dosage and frequency are defined based on the patient's current clinical need. Treatment is structured into distinct patterns:

Clinical Context	Dosing Regimen (600 mg tablet)	Frequency and Duration Pattern
Chronic Venous Insufficiency (CVI)	600 mg	Once daily (q.d.) for continuous, long-term support
Acute Hemorrhoidal Flare-up (Initial)	600 mg	Three times daily (t.i.d.) for a short course of 4 days
Acute Hemorrhoidal Flare-up (Follow-up)	600 mg	Twice daily (b.i.d.) for a subsequent course of 9 days

Administration Requirements

All doses of Vendios must be taken with meals at mealtimes to ensure correct administration. The distinction between the short-term, high-intensity use (lasting approximately 13 days) for acute episodes and the long-term, once-daily use for chronic support defines the overall protocol for this medication. Dose adjustment rules for specific populations, such as those with hepatic or renal impairment, are not explicitly detailed for this specific regimen, indicating that the standard adult dose applies.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vendios

Evidence for Symptomatic Support in Chronic Venous Insufficiency (CVI)

This section will summarize the available clinical research, primarily focusing on randomized controlled trials (RCTs) and meta-analyses, that have studied the effects observed when Vendios was administered to patients with CVI symptoms like leg heaviness, pain, and swelling (edema).

Research explored how the active ingredient in Vendios was evaluated in studies examining patient-reported outcomes related to physical discomfort and functional imbalance. These studies monitored changes in perceived discomfort, such as leg heaviness and pain, as well as objective measurements related to swelling (edema) over defined time intervals. Findings describe patterns observed in the studies related to subjective symptom scores and changes in objective measures, such as reported measurements of leg volume or circumference. This research provides insight into short-term changes.

However, certainty remains low regarding the long-term impact on the condition itself. Follow-up durations were limited in many studies, typically lasting only a few months. Long-term effects are not fully established, and evidence is limited concerning the substance’s role in preventing the progression of CVI. Furthermore, evidence quality varies across studies, and sample sizes were modest in some of the older research, meaning results apply only to the specific populations studied.

Evidence for Acute Symptom Management in Hemorrhoidal Disease

This part will outline the research landscape, including relevant clinical trials, which have examined the effects observed when Vendios was administered during episodes of hemorrhoidal disease, such as discomfort and bleeding duration.

Vendios was studied for its use during periods of increased symptom activity. Research was conducted during episodes where symptoms become more noticeable, such as acute bleeding and localized pain. Research monitored the time intervals until changes in symptom status were reported in the observed populations. Studies monitored how symptoms evolved in the observed populations, particularly outcomes linked to inflammatory or irritative states. Research contributes to the broader evidence landscape regarding symptoms associated with conditions involving periods of heightened symptoms.

What is Still Uncertain About the Research for Vendios

A key limitation is the absence of comprehensive long-term evidence describing outcomes over many years. Follow-up durations were limited in numerous trials, especially those relevant in trials assessing short-term or episodic symptom patterns. Comparative evidence is lacking for certain scenarios, and data for special populations remain insufficient. Research does not determine whether an individual will respond similarly, and study results reflect the specific conditions under which they were conducted.

Key Studies & References WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification C05CA - Bioflavonoids

Frequently Asked Questions (FAQ)

Common questions about Vendios (FAQ)

Q: Is Vendios generally considered a long-term or short-term treatment?

A: Official regulatory documents define distinct patterns of use for this medicine. It is prescribed using a continuous, long-term regimen for the support of Chronic Venous Insufficiency (CVI). Separately, a short-term, high-intensity course is documented for managing acute hemorrhoidal flare-ups.

Q: Is it normal to feel slightly nauseous when first starting Vendios?

A: Nausea is listed in official documents as a Common adverse reaction. This means it has been reported in up to 1 in 10 users. Concerns about persistent or severe effects are generally addressed by speaking with a healthcare professional.

Q: Are headaches a common side effect of Vendios?

A: According to official regulatory classifications, headaches are listed as a Rare adverse reaction. Rare effects are those reported in up to 1 in 1,000 users.

Q: Can you take Vendios if you have liver or kidney issues?

A: Official prescribing information indicates that standardized dose adjustment rules for specific populations, such as those with hepatic (liver) or renal (kidney) impairment, are not explicitly detailed in the standardized labeling. Regulatory documents suggest that use in patients with severe hepatic or renal impairment may require cautionary review by a healthcare professional.

Q: Does Vendios have a black box warning from the FDA or similar agency?

A: Official safety statements note that no adverse event associated with this medicine has been classified as an Important Identified Risk in official Risk Management Plans. The active ingredient is not currently subject to a black box warning from the FDA or equivalent agencies.

Q: Why does the official leaflet list so many possible side effects?

A: Regulatory guidelines require that official leaflets list all adverse events reported during clinical studies and post-marketing surveillance. These are classified by the frequency with which they were observed. This ensures patients have access to the full scope of information, even for effects that are very rare.

Q: What should I do if a side effect of Vendios feels severe?

A: Official safety information describes severe allergic reactions, such as Quincke's oedema (angioedema), as events that require emergency medical assessment. Concerns about any side effect are generally addressed by seeking professional medical guidance.

Q: What is the role of Vendios in a full treatment plan for the condition?

A: Vendios is classified as a phlebotropic and venotonic drug. Its primary general purpose is to improve the functional health of the venous system through vascular toning and capillary protection. It is used for the symptomatic support of conditions such as Chronic Venous Insufficiency (CVI) and acute hemorrhoidal episodes.

Q: Are there common feelings or sensations associated with starting Vendios?

A: Common adverse reactions reported in official documents, affecting up to 1 in 10 users, frequently involve the digestive system. These sensations include nausea, vomiting, diarrhoea, and dyspepsia (indigestion).

Q: Can Vendios be taken with regular vitamins or supplements?

A: Official product information reports that no clinically relevant drug interactions have been observed with other medicinal products. Formal restrictions regarding co-administration with other non-medicinal products, such as vitamins or supplements, are not documented.

Q: How long does Vendios stay in the body after the last dose?

A: Pharmacokinetic data from official sources describes the elimination rate of the drug. The plasma elimination half-life of the active substance’s major metabolite is indicated to be approximately 26 to 43 hours.

Q: What does the research say about the long-term use of Vendios?

A: Research reviews indicate that while studies have explored short-term effects, the duration of follow-up was limited in many trials, meaning comprehensive evidence describing outcomes over many years is absent.

Q: Is Vendios a controlled substance?

A: The active ingredient in Vendios is not listed as a controlled substance in US or international regulatory schedules. This classification relates to the potential for abuse or dependence.

Q: Are there any specific foods or drinks that should be avoided while on Vendios?

A: Official product information states that no formal restrictions, prohibitions, or mandatory avoidance rules are documented regarding interactions with specific foods or drinks. The administration conditions, including taking the medicine with meals, are outlined in the 'How to Use Vendios' section.

Q: What is the risk of dependence or withdrawal symptoms associated with Vendios?

A: There is no mention of dependence or the possibility of withdrawal symptoms in the official regulatory safety documents for Vendios.

Q: Does taking Vendios affect my ability to drive or operate machinery?

A: The official safety profile includes rare nervous system effects such as dizziness and headache. However, official prescribing information does not list formal restrictions regarding the ability to drive or operate machinery.

Q: What information is publicly available about the clinical trials for Vendios?

A: Information about registered clinical trials for the active ingredient is publicly available on government-run databases. This includes ClinicalTrials.gov, which is maintained by the National Institutes of Health (NIH).

Q: Are there different strengths or formulations of Vendios?

A: The Vendios preparation specifically discussed in the official documents is defined as a 600 mg film-coated tablet for oral administration. The official product labeling contains comprehensive details on all forms and strengths.

Q: What are the main things researchers looked at in studies of Vendios?

A: Research primarily examined patient-reported outcomes for Chronic Venous Insufficiency (CVI) symptoms like leg heaviness, pain, and swelling (edema). Studies also investigated effects observed during acute episodes of hemorrhoidal disease.

Q: Can Vendios be taken with birth control pills?

A: Official product information consistently reports that no clinically relevant drug interactions have been observed or reported with other medicinal products. Questions regarding co-administration with other medications, including hormonal contraceptives, are generally addressed by a healthcare professional.

Q: Is Vendios known to interact with herbal supplements like St. John's Wort?

A: Official product information states that no formal restrictions, prohibitions, or mandatory avoidance rules are documented regarding interactions with herbal products. Guidance on the use of herbal supplements alongside the medicine is typically provided by a healthcare professional.

Q: What if Vendios doesn't seem to be helping my condition?

A: For acute symptomatic use, official documentation states that a failure of symptoms to resolve requires re-evaluation of the clinical status. Failure of symptoms to resolve is a circumstance for which clinical re-evaluation is documented in official prescribing information.

Q: Is it okay to drink alcohol while taking Vendios?

A: Official product information confirms that no formal restrictions, prohibitions, or mandatory avoidance rules are documented regarding the consumption of alcohol while taking this medicine. The administration conditions, including taking the medicine with meals, are outlined in the 'How to Use Vendios' section.

Q: How soon after stopping Vendios are the drug effects considered gone?

A: Pharmacokinetic data provides information on how long the substance remains in the body, with the plasma elimination half-life of the active metabolite being approximately 26 to 43 hours. The duration of therapeutic effects is typically reviewed as part of a patient's overall clinical profile.

How should Vendios be stored and disposed of?

How to Store and Dispose of Vendios?

Vendios must be stored and handled according to the following official requirements to ensure product integrity and public safety, as defined by regulatory labeling.

Storage Conditions

Temperature: The product must be stored at a temperature that does not exceed 30 C (86 F).
Environmental Protection: The tablets must be protected from both light and moisture and should remain in the original container.
Child Safety: It is mandatory to store the medication out of the sight and reach of children.

Disposal Instructions

General Disposal: Unused or expired Vendios should be disposed of immediately using a medicine take-back program where available.
Environmental Protection: The product must not be disposed of via wastewater or thrown directly into household trash to prevent environmental contamination.

Vendios